Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI, FVT

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting


HAMILTON, ON and BOSTON, March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Presentation at AACR Annual Meeting 2024:

Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Session: Phase II Clinical Trials 1
Session Date and Time: Tuesday April 9, 2024, 9:00 a.m ? 12:30 p.m. PT
Location: Poster Section 49
Abstract Number: CT224

The poster will be available on Fusion's website following the presentation. For more details about the AACR Annual Meeting, please visit: https://www.aacr.org/meeting/aacr-annual-meeting-2024/.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical-stage development portfolio includes lead program, FPI-2265, targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer currently in a Phase 2 trial and novel targeted alpha therapies (TATs) including next-generation antibody drug conjugates (ADCs). Fusion has a collaboration with AstraZeneca to jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA damage response inhibitors and immuno-oncology agents. Fusion has a fully operational Good Manufacturing Practice compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for  the Company's growing pipeline of TATs. The Company has strategic actinium supply agreements with Niowave, Inc. and BWXT Medical.

Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
[email protected]

SOURCE Fusion Pharmaceuticals


These press releases may also interest you

at 07:35
Nutanix and Dell Technologies Collaborate on New Joint Solutions for Hybrid Multicloud
.NEXT Conference ? Nutanix , a leader in hybrid multicloud computing, today announced a collaboration with Dell Technologies aimed at accelerating customers' digital transformation journeys fueled by infrastructure modernization and modern...

at 07:35
Nutanix Simplifies Management and Operations of Kubernetes Clusters Anywhere to Speed Innovation
.NEXT Conference ? Nutanix , a leader in hybrid multicloud computing, today announced Nutanix Kubernetes® Platform (NKP) to simplify management of container-based modern applications using Kubernetes. NKP enables customers to innovate faster with a...

at 07:35
Nutanix and EDB Partner to Deliver a Modern Data Platform
.NEXT Conference ? Today, Nutanix , a leader in hybrid multicloud computing, and EnterpriseDB ("EDB"), a leader in accelerating PostgreSQL in the enterprise, announced an expanded partnership that aims to enable customers to harness the power of...

at 07:35
Nutanix Adds Power Monitoring to Help Customers Track Sustainability Progress
.NEXT Conference ? Nutanix , a leader in hybrid multicloud computing, today announced new capabilities in Nutanix Cloud Platform that will deliver visibility of the power consumption of a Nutanix environment. This will help organizations improve...

at 07:35
Nutanix and NVIDIA Collaborate to Accelerate Enterprise AI Adoption
.NEXT Conference ? Nutanix , a leader in hybrid multicloud computing, today announced a collaboration with NVIDIA aimed at helping enterprises more easily adopt generative AI (GenAI). Through the integration of NVIDIA NIM inference microservices with...

at 07:35
Nutanix Accelerates Hypervisor Innovation to Drive Enterprise Modernization
.NEXT Conference ? Nutanix , a leader in hybrid multicloud computing, today announced new Nutanix AHV deployment options and programs to help customers fast-track infrastructure modernization by reusing existing server hardware investments, while...

More news about Science and technology...


News published on and distributed by: